Abstract
Tarlatamab (AMG 757) binds DLL3 on SCLC cells and CD3 on T cells leading to T cell-mediated tumor lysis. Updated phase 1 tarlatamab data in relapsed/refractory SCLC showed an ORR of 23%, median DOR of 13 months, and an acceptable safety profile with cytokine release syndrome (CRS) as the most common treatment-related (TRAE).1 Here, we describe clinical CRS seen with tarlatamab and explore associations between cytokine levels and CRS in cycle 1 (C1)-where CRS mostly occurs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
